Notable Thursday Option Activity: WFC, SITM, VKTX

SiTime (SITM) options traded 1,198 contracts (~119,800 underlying shares), about 43.2% of its one‑month average daily volume (277,630 shares), led by 151 contracts in the $280 call expiring Feb 20, 2026 (~15,100 shares). Viking Therapeutics (VKTX) saw 13,638 option contracts (~1.4M underlying shares), about 42.6% of its one‑month ADTV (3.2M shares), with the Feb 6, 2026 $26.50 call accounting for 2,286 contracts (~228,600 shares). The concentration of call activity in these strikes and expirations indicates notable speculative/bullish positioning that could influence near‑term price moves in both names.

Analysis

Market structure: Heavy concentrated call volume in SITM (1,198 contracts ≈119.8k shares, 43% of ADTV) and VKTX (13,638 contracts ≈1.36M shares, 42.6% of ADTV) signals directional speculative demand that will mechanically compress bid liquidity and amplify intraday moves via dealer delta-hedging. Winners are short-dated call sellers/market-makers collecting premium and any buyers who correctly forecast catalysts; losers are passive holders caught in gamma-driven squeezes if flows reverse. Cross-asset impact is limited but expect transient equity-index skew shifts and small upward pressure on implied correlation; bond/FX moves negligible absent macro news.

Risk assessment: Tail risks include trial failure or negative data for VKTX and sector-wide volatility spike; for SITM, product/competitive setbacks or a deal rumor failure could produce >30% drawdowns. Immediate (days) risk is short-term gamma; short-term (weeks–months) risk centers on IV crush around catalysts; long-term (quarters) depends on fundamentals—revenues, trials, M&A. Hidden dependency: large call buys are often delta-hedged by dealers selling stock, creating feedback loops that can reverse violently when positions unwind.

Trade implications: For VKTX, the flow suggests directional bullishness—prefer defined-risk bullish spreads into Feb 2026 to limit theta and IV exposure; for SITM, concentrated OTM call activity suggests either event-driven play or volatility sell opportunity—use defined-risk credit spreads or covered calls if long equity. Pair trades: long VKTX call spread vs short biotech ETF exposure to strip sector beta. Entry window: act within 7 trading days while flow persists; set profit targets 30–80% and hard stops at 40–60% premium loss.

Contrarian angles: The market may be over-attributing informational content to option volume—single large buyers can create illusions of consensus; implied vol may be rich and offer selling opportunities with defined risk. Historical parallel: 1-year OTM call clusters preceded both successful M&A outcomes and busted biotech rallies; absent corroborating open-interest/institutional filings, treat as high-skew speculative flow. Unintended consequence: aggressive selling of premium can be gamma-negative and exacerbate downturns if a true positive catalyst emerges.

Key Decisions for Investors

• Establish a 0.75% portfolio position: buy VKTX Feb 06 2026 26.50/40.00 call debit spread (defined-risk). Rationale: captures the directional call flow while capping theta; target 50–100% return, stop-loss at 50% premium loss or immediate exit on any negative trial/clinical news.
• If you hold or plan to buy SITM equity, implement covered-call overlay at the Feb 20 2026 $280 strike to collect premium (size 0.5–1% of portfolio). Alternatively, if unallocated, sell a Feb 20 2026 $280/$320 bear call spread (size 0.5%), but only if IV >35% and credit ≥ market bid; close if SITM >$280 or IV rises >20%.
• Execute a hedged pair: offset 50–70% sector beta by shorting 0.5% notional of IBB (iShares Nasdaq Biotechnology) when initiating the VKTX call spread to isolate idiosyncratic upside and limit sector drawdown risk.
• Only initiate or add to these option trades within the next 7 trading days while options volume and OI acceleration persist; require OI uptick ≥15% over 3 days or IV percentile >40 to validate flow. Liquidate positions if IV contracts >20% without price confirmation or if adverse catalyst occurs.